Financial Health vs. Weight Loss: Study Finds Americans Prioritize GLP-1 Debt Over Emergency Funds

For many Americans, the monthly budget now includes a new, non-negotiable line item. Nearly 60% of adults say they would consider going into debt to afford an effective weight-loss medication, according to a recent survey of 1,008 people by Trimi Health. For users of GLP-1 receptor agonists like Wegovy and Zepbound, the prescription has shifted from a discretionary health expense to a priority that outranks traditional financial safety nets.

The financial commitment requires tangible sacrifices at the kitchen table. The study found that reaching a goal weight ranked above building an emergency fund or paying off debt when respondents were asked to choose a single financial priority for the year. To make room for the treatment, 59% of people said dining out was the first expense they would cut, followed closely by canceling subscriptions and delaying travel plans.

This shift in consumer spending is actively reshaping the broader wellness economy. A separate study by the Consumer Collective revealed that GLP-1 users spend an average of $449 a month on fitness across various categories, nearly four times the $120 monthly average spent by non-users.[3]

The lifestyle changes extend far beyond the pharmacy counter, altering daily routines. Eighty-one percent of GLP-1 users reported they were likely to pay for a gym membership, compared to just 43% of non-users. Millennials are leading this trend, reporting a 29% usage rate for the medications and spending $345 a month on fitness—the highest of any generation surveyed.[3]

These spending patterns reflect a broader rewiring of the healthcare industry. Usage of GLP-1 drugs surged by more than 140% from 2022 to 2024, according to a Wells Fargo report. "GLP-1s may be marketed as weight-loss drugs, but they're rapidly becoming one of the most disruptive economic forces in healthcare," John Teasley, market executive for Wells Fargo Healthcare Banking, told Fox Business. During that same two-year window, bariatric surgery volumes fell by 34.1%.[2]

The clinical benefits driving this demand are well-documented. The medications work by mimicking an incretin hormone naturally released in the intestine after eating, which slows gastric emptying and reduces appetite. Beyond weight loss, studies have demonstrated that the drugs provide cardiovascular risk reduction, kidney protection in diabetic populations, and improvements in obstructive sleep apnea.[1]

However, the long-term economic impact remains uncertain. While the health outcomes are real, the cost savings for employers and health plans are still unproven. "I'm pretty convinced that the GLP-1 drugs are improving the health of plan members, when taken appropriately," said Frédéric Leblanc, a pharmacist and strategic lead at iA, speaking to Benefits Canada. Yet in Canada, which recently became the first G7 country to approve a generic version of semaglutide, plan sponsors are still waiting for retrospective data to justify the investment.[1]

For individual consumers, the financial calculus is deeply personal. The Trimi survey noted that 80% of current GLP-1 users would be willing to pay for the treatment for the rest of their lives if it helped them maintain their weight loss. As the medications become a permanent fixture in American healthcare, the tension between funding immediate metabolic health and preserving long-term financial stability will require careful navigation.